Lokesh Jain

3.1k total citations
57 papers, 2.3k citations indexed

About

Lokesh Jain is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lokesh Jain has authored 57 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Lokesh Jain's work include Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Lokesh Jain is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Lokesh Jain collaborates with scholars based in United States, India and United Kingdom. Lokesh Jain's co-authors include William D. Figg, Jürgen Venitz, William L. Dahut, Elise C. Kohn, Seth M. Steinberg, Vikram Sinha, Erin R. Gardner, James R. Wright, William D. Figg and David Venzon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lokesh Jain

53 papers receiving 2.2k citations

Peers

Countries citing papers authored by Lokesh Jain

Since Specialization

Citations

This map shows the geographic impact of Lokesh Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lokesh Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lokesh Jain more than expected).

Fields of papers citing papers by Lokesh Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lokesh Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lokesh Jain. The network helps show where Lokesh Jain may publish in the future.

Co-authorship network of co-authors of Lokesh Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Lokesh Jain. A scholar is included among the top collaborators of Lokesh Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lokesh Jain. Lokesh Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial 2024 ·Annals of Oncology ·C. Le Tourneau, (unknown), C. Even, Assuntina G. Sacco, Amaury Daste, Irene Braña, C. van Herpen, Thibault Mazard, (unknown), (unknown), Andrew K. Joe, (unknown), (unknown), (unknown), Lokesh Jain, (unknown), Richard de Leeuw, Antoine Hollebecque	2
2	Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study 2024 ·PLoS ONE ·Graham Cohen, Bernardo L. Rapoport, (unknown), Paul Ruff, Ana Arance, (unknown), Baerin Houghton, Michael P. Brown, (unknown), Eva Muñoz‐Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, (unknown), Elliot Chartash, Conrad Jacobs	0
3	Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review 2023 ·Gastroenterology Insights ·(unknown), (unknown), Mukesh Jain, (unknown), Lokesh Jain, Anish Desai	6
4	Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Dhananjay Marathe, (unknown), Huub Jan Kleijn, (unknown), Anne Chain, Thomas J. Bateman, Peter Shaw, Anson K. Abraham, (unknown), Yanfang Liu, Rodolfo F. Perini, Dinesh P. de Alwis, Lokesh Jain	11
5	168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) 2021 ·Annals of Oncology ·Balázs Halmos, Patrick Cobb, Melissa L. Johnson, Lokesh Jain, (unknown), Sanatan Saraf, Mallika Lala, Takayasu Kurata	0
6	Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas 2021 ·Cancer Chemotherapy and Pharmacology ·Stein Schalkwijk, Li Zhou, (unknown), Lokesh Jain, Tomoko Freshwater, Karen So, (unknown), (unknown), Helen Tomkinson, Karthick Vishwanathan, Diansong Zhou	10
7	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study 2018 ·Clinical Cancer Research ·Michael B. Atkins, F. Stephen Hodi, John A. Thompson, Ray McDermott, Wen‐Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, (unknown), Shailender Bhatia, (unknown), Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas	48
8	Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance 2018 ·Clinical Cancer Research ·David C. Turner, Anna Kondic, Keaven M. Anderson, Andrew Robinson, Edward B. Garon, Jonathan W. Riess, Lokesh Jain, Kapil Mayawala, Jiannan Kang, Scot Ebbinghaus, Vikram Sinha, Dinesh P. de Alwis, Julie A. Stone	156
9	Pharmacokinetic Assessment in Patients Receiving Continuous RRT 2014 ·Clinical Journal of the American Society of Nephrology ·Thomas D. Nolin, George R. Aronoff, William H. Fissell, Lokesh Jain, (unknown), Kellie S. Reynolds, Lei Zhang, Shiew Mei Huang, Rajnish Mehrotra, Michael F. Flessner, John K. Leypoldt, Jennifer Witcher, Issam Zineh, Patrick Archdeacon, Prabir Roy‐Chaudhury, Stuart L. Goldstein	35
10	Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia 2012 ·Clinical Cancer Research ·Cody J. Peer, Tristan M. Sissung, AeRang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah Troutman, Bevin C. English, Emily D. Richardson, Joel D. Federspiel, David Venzon, William L. Dahut, Elise C. Kohn, Shivaani Kummar, Robert Yarchoan, Giuseppe Giaccone, Brigitte C. Widemann, William D. Figg	108
11	Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy 2012 ·Digestive and Liver Disease ·Lokesh Jain, Barjesh Chander Sharma, Praveen Sharma, Siddharth Srivastava, Amit Agrawal, Shiv Kumar Sarin	47
12	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas 2011 ·Clinical Cancer Research ·Arun Rajan, Ronan J. Kelly, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, Baskar Mannargudi, William D. Figg, Brett E. Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone	107
13	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib 2010 ·Journal of Experimental & Clinical Cancer Research ·Lokesh Jain, Tristan M. Sissung, Romano Danesi, Elise C. Kohn, William L. Dahut, Shivaani Kummar, David Venzon, David J. Liewehr, Bevin C. English, Caitlin E. Baum, Robert Yarchoan, Giuseppe Giaccone, Jürgen Venitz, Douglas K. Price, William D. Figg	82
14	The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters 2010 ·Anti-Cancer Agents in Medicinal Chemistry ·Lokesh Jain, Sophia Abraham, Stacy S. Shord	3
15	Clinical presentation and outcomes following posterior segment IOFB 2010 ·SHILAP Revista de lepidopterología ·Harsha Bhattacharjee, (unknown), (unknown), (unknown), (unknown), Lokesh Jain	2
16	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors 2009 ·Molecular Cancer Therapeutics ·Lokesh Jain, Craig Vargo, Romano Danesi, Tristan M. Sissung, Douglas K. Price, David Venzon, Jürgen Venitz, William D. Figg	146
17	Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer 2009 ·British Journal of Urology ·Jeanny B. Aragon‐Ching, Lokesh Jain, James L. Gulley, Philip M. Arlen, James R. Wright, Seth M. Steinberg, David E. Draper, Jürgen Venitz, Elizabeth C. Jones, Clara C. Chen, William D. Figg, William L. Dahut	91
18	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer 2008 ·Clinical Cancer Research ·William L. Dahut, Charity D. Scripture, Edwin M. Posadas, Lokesh Jain, James L. Gulley, Philip M. Arlen, James R. Wright, Yunkai Yu, Liang Cao, Seth M. Steinberg, Jeanny B. Aragon‐Ching, Jürgen Venitz, Elizabeth C. Jones, Clara C. Chen, William D. Figg	142
19	Indirect optic nerve injury in two-wheeler riders in northeast India 2008 ·Indian Journal of Ophthalmology ·(unknown), Kasturi Bhattacharjee, Lokesh Jain, (unknown), (unknown), (unknown), (unknown), (unknown)	17
20	Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasma 2007 ·Journal of Pharmaceutical and Biomedical Analysis ·Lokesh Jain, Erin R. Gardner, Jürgen Venitz, William L. Dahut, William D. Figg	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact